Comparing Efficacy and Safety of CTO0303 in Pediatric Subjects

NCT06609525 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

UNKNOWN

Status

156

Enrollment

INDUSTRY

Sponsor class

Conditions

Pupillary Dilation Effect During Cycloplegic Refraction

Interventions

DRUG: CTO0303-A
DRUG: CTO0303-B
DRUG: CTO0303-C

Sponsor

Taejoon Pharmaceutical Co., Ltd.